Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
6–20
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological diagnosis of GIST.
Patients must have demonstrated either disease progression or intolerance to imatinib mesylate, have non-mutant Stem Cell Factor Receptor gene (KIT) GIST, or cannot obtain imatinib in their country
Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable disease.
You may not be if
Current treatment with another investigational agent.
Prior sunitinib treatment.
Prior therapy with known risk for cardiovascular complications.
